News and insights
At Johnson & Johnson, we are building a world where complex diseases are prevented, treated and cured. Where treatments are smarter and less invasive—and solutions are personal.
Discover our most recent updates, learn about groundbreaking innovations and meet some of the dedicated individuals who make it all happen.
Discover our most recent updates, learn about groundbreaking innovations and meet some of the dedicated individuals who make it all happen.
-
What you need to know about Johnson & Johnson’s third-quarter 2026 earnings report
Check out this infographic breakdown of the company’s third-quarter performance, with highlights from its Innovative Medicine and MedTech businesses. -
How a family history of heart disease and stroke drives the work of 3 Johnson & Johnson scientists
Cardiovascular disease is the leading cause of death around the world. For Roberta Chapman, Alistair Lindsay and JoAnne Foody the pursuit of better treatments is both a professional mission and a deeply personal one.
-
Inside the development of Johnson & Johnson’s OTTAVA™ Robotic Surgical System
Built to expand OR capacity, maintain procedural momentum and elevate performance, OTTAVA™ is opening new possibilities in surgery. Neda Cvijetic, Global Head of Robotics & Digital R&D, MedTech at Johnson & Johnson, explains what surgeons need to know. -
More than memory loss: 5 things we now know about Alzheimer’s disease
Scientists are better understanding the neuropsychiatric changes that strike up to 97% of patients diagnosed with this degenerative brain disease. Here’s what to know about these often distressing symptoms, and why Johnson & Johnson is working on a solution.
More from Johnson & Johnson
Johnson & Johnson’s ICOTYDE® (icotrokinra) named to Time’s Best Inventions of 2026 list
The first-of-its-kind targeted oral peptide therapy for moderate to severe plaque psoriasis has been chosen for the annual list, which recognizes innovations for their originality, ambition and impact.
A behind-the-scenes look at how Johnson & Johnson manufactures and delivers CAR-T cell therapy for multiple myeloma
Transforming cancer patients’ own cells into a targeted treatment is a complex and nuanced process. Jessica Torfs, director of Global CAR-T Supply Chain at Johnson & Johnson, explains what it takes to deliver this cutting-edge personalized therapy.
When depression improves but patients still grapple with symptoms
Only one in three people with major depressive disorder achieves remission after their first antidepressant, leaving many to continue to experience life-impacting symptoms such as disrupted sleep, changes in weight and appetite and trouble concentrating. Learn why Johnson & Johnson is working to help more patients achieve remission.
The science behind targeted oral peptides
A new type of medication is tackling a problem that has long frustrated drug developers: how to deliver peptide therapies orally and hit their target more precisely.
The IBD resource many patients say they can’t live without
Inflammatory bowel disease (IBD) is often described as an “invisible illness” due to symptoms that aren’t always apparent to others. But for the millions living with the disease, the impact goes beyond physical symptoms. Learn how Johnson & Johnson is helping create a patient community for those dealing with the heavy psychological toll of IBD.
Johnson & Johnson named to The Wall Street Journal’s 2026 Best Companies for the Future list
The company’s ability to evolve as it tackles the world’s toughest health challenges has helped Johnson & Johnson earn its spot as the top-ranked healthcare company on the list.